Prevail Therapeutics Inc

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN).

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation for PR006 for the treatment of frontotemporal dementia (FTD). PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN).

Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on November 17, 2020 issued a composition of matter patent, U.S. Patent No. 10,837,028, with claims directed to the AAV vector used in PR001, Prevail's experimental gene therapy program for the treatment of Parkinson's disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings.

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson's Disease with GBA1 Mutations

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December:

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease (nGD). The Company expects to initiate enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 for Type 2 neuronopathic Gaucher disease patients in the second half of 2020.

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

NEW YORK, Sept.  18, 2020  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020 at 2:30 p.m. ET.

Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) --  Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H. Carson, M.D., to its Board of Directors.

Prevail Therapeutics Announces Appointment of William H. Carson, M.D.

Prevail Therapeutics Inc.'s (PRVL) CEO Asa Abeliovich on Q2 2020 Results - Earnings Call Transcript

Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity  in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients

Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

NEW YORK, Aug.  05, 2020  (GLOBE NEWSWIRE) --  Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will present at the virtual 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 1:45 p.m. ET.

Prevail Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug.  05, 2020  (GLOBE NEWSWIRE) --  Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the company will host a conference call and live webcast on Tuesday, August 11, 2020, at 7:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates.

Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results

Gene Therapy is Being Developed for the Treatment of Frontotemporal Dementia patients with GRN Mutations Gene Therapy is Being Developed for the Treatment of Frontotemporal Dementia patients with GRN Mutations

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006

Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher on Thursday after the company reported it will highlight multiple gene therapy programs for neurodegenerative diseases at the 2020 Alzheimer's Association International Conference.

Why Prevail Therapeutics Is Trading Higher Today

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases

Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference

Ms. Schwartz brings over 16 years of legal experience in the biopharma industry to Prevail’s leadership team Ms. Schwartz brings over 16 years of legal experience in the biopharma industry to Prevail’s leadership team

Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel

Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing;  Study  Startup ActivitiesProgressing for Phase 1/2 Trials of PR001 for Type 2 Neuronopathic Gaucher Disease and PR006 forFrontotemporal Dementia with GRN Mutations

Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights

As of late, it has definitely been a great time to be an investor in Prevail Therapeutics Inc. (PRVL).

Prevail Therapeutics Inc. (PRVL) Shares March Higher, Can It Continue?

Prevail Therapeutics (PRVL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Prevail Therapeutics (PRVL) Stock Might be a Great Pick

NEW YORK, March  24, 2020  (GLOBE NEWSWIRE) --  Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s experimental gene therapy program, PR006, to slow the progression of frontotemporal dementia with a GRN mutation (FTD-GRN). Prevail announced an active IND for the Phase 1/2 clinical trial of PR006 for the treatment of FTD-GRN  earlier this month .

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation

Prevail Therapeutics: A Speculative Buy For Its Disease-Modifying Gene Therapies For Neurodegenerative Diseases

NEW YORK, March  02, 2020  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its experimental gene therapy program, PR006, for the treatment of frontotemporal dementia patients with GRN mutation (FTD-GRN), and that the Company may proceed with the initiation of its Phase 1/2 clinical trial.

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

NEW YORK, Feb.  21, 2020  (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that management will present at two upcoming conferences:

Prevail Therapeutics to Present at Upcoming Conferences

Orphan Drug Designation Granted for Treatment of Gaucher Disease 

Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA

PR001 Administered to International Type 2 Gaucher Disease Patient  Via Compassionate Use Pathway

News for Prevail Therapeutics Inc Stock (PRVL)